

**The Risk & Compliance Pharma & Life Sciences Conference**  
2 October 2025 | Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT



## Welcome To The Risk & Compliance Pharma & Life Sciences Conference

### Official Event Programme

Please note that the following timings are flexible. Due to the nature of a live event, the conference chairs and organisers will be updating the timings throughout the day to adapt to speakers running over time, late arrivals, last minute changes and extending popular sessions. Please rest assured we will do our utmost to adapt and to accommodate all live changes.

Organised By:



**08.15 Registration & Ethixbase360 VIP Networking Breakfast**



**09.00 GIC Welcome & Morning Chair's Opening Remarks**

Alex Davison, Compliance Director Europe & Global Projects, **Amarin**



**Geopolitics & International Risk – Panel & Q&A**

**09.10 Increase Your Proactivity & Agility In Navigating Uncertain Times By Effectively Preparing For Global Pharma Regulatory Developments In A Volatile Geopolitical Landscape**

- From elections to conflict and tariffs to sanctions, discuss and debate how to monitor a rapidly changing and turbulent geopolitical landscape in order to anticipate the impact of operating a global business in a divided world
- Ensure operational continuity and ethical standards to remain steadfast in the face of potential instability and disruption
- Deep dive into the implications for your functions: not only remaining abreast of the global developments but navigating the potential consequences for your operations to develop and evolve
- Proactivity not reactivity: craft agile frameworks and innovative ideas to effectively anticipate and respond to ever-changing circumstances

Lucy Sales, Senior Director - Risk & Compliance, **AstraZeneca**



Anastasia Troyan, Senior Director Global Compliance & Ethics, **Teva**



Gabor Sulyok, Global Head of Commercial and Healthcare Compliance,  
**BioNTech SE**



Tetiana Isaieva, Head of Compliance EEMEAIS, **Roche**



Evan Flowers, Partner, **Dechert LLP**



## AI & Automation

### 09.50 Harness The Practical Potential Of AI & Master Regulatory Framework Development To Advance AI Adoption Across All Functions

- Move beyond discussing the theoretical implications of AI to discover best practices for using AI to streamline operations and maximise efficiencies
- Navigate current and upcoming AI legislation to anticipate what the next regulatory updates may focus on, and ensure compliance through the adoption and implementation of AI strategies
- Monitor the regulatory challenges in digital therapeutics and AI-driven drug discovery, and ensure that AI usage complies with data security policies to advance AI usage while complying with regulatory requirements
- As the capabilities of AI continue to evolve and change, how can you develop and enforce robust, ethical and compliant AI policies?

Alexis Pagé, Business Ethics Director, **Ipsen**



## ABPI Regulatory Updates & Trends

### 10.10 Patients & Public Engagement: Health Information Landscape

- Gain an exclusive insight into the current research by the ABPI into patients and public engagement
- Foster improved patient and public engagement while remaining wholly compliant with regulatory requirements
- Evaluate the potential role of 'influencers' in promoting products
- Is social media the key? In a world where misinformation is rife and people rely on AI for medical advice, should the rules be changed to pharmaceutical companies be able to directly communicate accurate information to the public?
- Do the current laws on patient engagement reflect the current needs and nature of society?

Andy Collier, Senior Policy Manager – Reputation, **The Association of the British Pharmaceutical Industry**



### Finding Smart Moves To Help People Do The Right Thing

**10.30 Adopt An Agile And Practical Approach To Help The Humans In Your Organisation Use Choices And Actions That Protect Them, The Business, And Your Customers.**

- The current change and disruption in pharma and life sciences is increasing the risk of ‘wrongdoing by good people’. How can you cut through the noise and help people do the right thing?
- An agile and practical approach, rooted in behavioural science, will help you find the small actions that make a big difference.
- You can move with pace and focus to help people do the simple things that help them navigate the regulatory environment and keep your organisation, safe.
- The best answers don't always require large budgets or take lots of time. We'll share examples from organisations that found smart moves to drive change, save time and save money.

Owen Rose, Director, **Acteon**




### 10.45 Morning Refreshment Break With Informal Networking

# Acteon

## Shape the moments that matter

We create **learning** and **communication campaigns** to **engage** people, and to help them to **act in the moment**.



Whatever you need employees to do, we partner with you to prompt the actions that will support positive change.

Our experienced consultants partner with you to build insight into how to achieve the impact you need. We bring the digital and creative skills to identify, design and deliver solutions from comms campaigns to music videos, workshops to animated movies, interactive digital experiences or something else altogether.

Whatever your business needs, drop us a line to chat about how we can help.

[www.acteoncommunication.com](http://www.acteoncommunication.com)

[hello@acteoncommunication.com](mailto:hello@acteoncommunication.com)





## **Data Integrity, Analysis & Ethics – Delegate Discussion**

### **11.15 Proactive Data Integrity Approaches To Ensure Watertight Compliance Standards & Increased Patient Trust In An Increasingly Complex, International & Tech-Driven Data Landscape**

*We would encourage you all to enter into the spirit of the day and to share ideas with fellow delegates. We understand there might be commercial sensitivities behind discussing strategies, however, there is a lot to be gained from sharing theories, mindsets and abstract situations – the person sat next to you might just have that fresh outlook which unlocks new potential!*

## **Regulatory Updates & Trends – Panel & Q&A**

### **11.35 Stay Ahead Of The Curve & Unpack The Latest Regulatory Updates & Adopt A Dynamic Perspective To Consider What The Current Trends Mean For The Future Of Risk & Compliance**

- Adopt a broader perspective on the changes occurring within the risk and compliance landscape: unpack the latest legislation coming into force in this industry and develop the most effective strategies for navigating any implications or consequences for your functions
- Discuss and debate the most pertinent legislation affecting this field and navigate the consequences and impact for your operations
- What's next? Evaluate the current regulatory trends and discuss the future of the risk and compliance landscape to keep pace and evaluate the future of these functions in the face of global compliance challenges

Meredith Kennedy, Head of Compliance Eu Nth/Sth & Vice Chair of the EFPIA Ethics & Compliance Committee, **Roche Pharma**



**The Risk & Compliance Pharma & Life Sciences Conference**  
2 October 2025 | Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Alicia White, Director, **PMCPA**



Corlia Van Der Walt, Director: R&D Partnerships & Legal Compliance,  
**AstraZeneca**



Rashmi Papneja, Managing Director, **Eunomia Pharma Services**



Sasi-Kanth Mallela, Managing Director, **Ankura**





### Third-Party Risk Management – Double Perspective

#### 12.15 Facilitate Rigorous Monitoring & Robust Relationships With Third Parties To Optimise Compliance Strategies Across A Global Supply Chain

- Apply proactive risk assessments and rigorous monitoring to ensure thorough due diligence and high standards for third parties
- Combine effective monitoring and due diligence with new strategies to dynamically foster constructive and compliant third-party relationships
- Expand your vision of third-party risk management to encompass a global perspective and develop a holistic approach that ensures high ethical, safety and compliance standards across an international scale
- What is the next evolution in third-party risk management? From intermediaries to sub-contractors and beyond... develop forward-thinking perspectives on the expansion and advancements in third-party risk management to assess the future of compliant relationships with partners


#### 12.15 Perspective 1

Natalia Cojucaru, Senior Director, Ethics & Compliance, **Novo Nordisk**



#### 12.35 Perspective 2

Lizanne Pistorius, Head of Patient Safety & Pharmacovigilance, **Boehringer Ingelheim**



### 12.55 Topic Generation Submission

*We would love to hear your thoughts on potential topics or ideas for one-day brand-led conferences – please do submit any thoughts or ideas via the QR code on the screen. Many thanks in advance!*

### 13.00 Lunch & Informal Networking For Speakers, Delegates & Partners

### 13.30 Interactive Hot Topic Peer-To-Peer Discussion

#### a) Auditing Inspections

Vinod Koshy, Director, Global Healthcare Compliance, **Advanz Pharma**



### 14.00 Afternoon Chair's Opening Remarks

Kyriaki (Kiki) Merakli, Chief Compliance Officer, **Sobi**



**Anti-Corruption & Anti-Bribery – Panel & Q&A**

**14.10 Ensure Stringent Standards On Anti-Corruption & Anti-Bribery & Effectively Monitor Upcoming Regulatory Developments To Foster Adaptive Decision-Making Strategies**

- Navigate the changes in the anti-corruption legislation and prepare for relevant developments in the geopolitical landscape to foster proactive and adaptive decision-making strategies across all functions
- How have things changed in light of the suspension and limitation of the Foreign Corrupt Practices Act in the US? What are the implications for European approaches to anti-corruption and anti-bribery?
- Ensure rigorous compliance with anti-corruption laws and develop robust tactics to monitor risks and maintain stringent standards across the organisation

Patrick Wellens, Chairman, **Ethics and Compliance Switzerland**



Norbert Kaliwe, Director Compliance & AML Lead, **Merck**



David Symes, Chartered Accountant & former FTSE 100 Deputy Head of Compliance, MD, **Compliance Recruitment Solutions**



Natasha Martin, Head of Product & Proposition, **EthixBase360**



#### 14.50 Interactive Hot Topic Peer-To-Peer Discussions

##### a) Patient-Centric Compliance

Meredith Kennedy, Head of Compliance Eu Nth/Sth & Vice Chair of the EFPIA Ethics & Compliance Committee, **Roche**



##### b) Cyber Security

Kyriaki Merakli, Chief Compliance Officer, **Sobi**



**c) Global Compliance Challenges**

Alex Davison, Compliance Director Europe & Global Projects, **Amarin**



**d) Monitoring**

Yaroslav Drozdov Business Ethics Director Russia / CIS / Middle East and Africa,  
**Ipsen**



**HCP Interaction & Engagement – Perspective 1**

**15.20 Ethics, Integrity & Transparency: Facilitate Ethical Interactions & Constructive & Compliant Relationships With HCPs**

- Mitigate risks in interactions with HCPs and develop effective methods to ensure and enhance rigorous compliance in every aspect of HCP interaction and engagement
- Delve into the best practices in HCP engagement to cultivate holistic compliance strategies and prioritise ethics-driven decision making
- Navigate the changing media landscape as the media take an increasing interest in the relationship between pharma companies and payments to HCPs. How has this impacted the interactions with HCPs?

Charles-Edouard Castaigne, Head of Internal Audit Global Business Units,  
**Sanofi**




### Data Integrity & Compliant Data Storage

#### 15.40 Bonus Session With Exclusive Conference Partner Anton Paar Ltd

- Explore the challenges of data integrity and compliant data storage in pharmaceutical testing
- Discover Anton Paar's solution AP connect and how it works as a single vehicle for compliant data collection from multiple different equipment vendors

Stefan Thaler, Head of Lab Productivity Systems, **Anton Paar Ltd**



### 15.55 Evaluation Form & Feedback

*We would love to hear your thoughts on potential topics or ideas for one-day brand-led conferences – please do submit any thoughts or ideas via the QR code on the screen. Many thanks in advance!*

### 16.00 Afternoon Refreshment Break With Informal Networking

### ESG & Sustainability Compliance – Delegate Discussion

#### 16.30 Ensure ESG Compliance In A Changing Sustainability Landscape & Foster A Proactive Approach To Maintaining Effective Monitoring & Initiatives

*We would encourage you all to enter into the spirit of the day and to share ideas with fellow delegates. We understand there might be commercial sensitivities behind discussing strategies, however, there is a lot to be gained from sharing theories, mindsets and abstract situations – the person sat next to you might just have that fresh outlook which unlocks new potential!*



## HCP Interaction & Engagement – Perspective 2

### 16.50 Ethics, Integrity & Transparency: Facilitate Ethical Interactions & Constructive & Compliant Relationships With HCPs

- Mitigate risks in interactions with HCPs and develop effective methods to ensure and enhance rigorous compliance in every aspect of HCP interaction and engagement
- Delve into the best practices in HCP engagement to cultivate holistic compliance strategies and prioritise ethics-driven decision making
- Navigate the changing media landscape as the media take an increasing interest in the relationship between pharma companies and payments to HCPs. How has this impacted the interactions with HCPs?

Jacob Jose Palathingal, Director – Risk Insights & Reporting, **Novartis International**



 **NOVARTIS**

## 17.10 Afternoon Chair's Closing Remarks & Official Close Of Conference

Kyriaki (Kiki) Merakli, Chief Compliance Officer, **Sobi**



 **sobi**  
rare strength